LeMaitre Vascular (NASDAQ:LMAT) Downgraded by Oppenheimer to “Market Perform”

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities researchers at Oppenheimer from an “outperform” rating to a “market perform” rating in a report released on Friday,Briefing.com Automated Import reports.

Several other brokerages have also weighed in on LMAT. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Trading Down 3.0 %

Shares of NASDAQ LMAT opened at $99.91 on Friday. The stock has a fifty day simple moving average of $96.90 and a two-hundred day simple moving average of $94.66. LeMaitre Vascular has a 1-year low of $62.39 and a 1-year high of $109.58. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of 54.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. Analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently made changes to their positions in LMAT. Smartleaf Asset Management LLC raised its position in shares of LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC raised its position in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 117 shares in the last quarter. KBC Group NV raised its position in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 410 shares in the last quarter. Huntington National Bank raised its position in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 455 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of LeMaitre Vascular in the fourth quarter worth $150,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.